Latest Period
Q1 2026
Security Snapshot
Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) Institutional Ownership
CUSIP: 01626L204
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
34
Shares (Excl. Options)
2,775,086
Price
$7.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value, $0.0001 per share
- Symbol
- ALGS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,775,086
- Total 13F value
- $20,618,673
- Portfolio coverage rank
- 0%
- Share change
- -42,805
- Value change
- -$479,274
- Number of holders
- 34
- Shares outstanding
- 5,612,020
- SEC-reported price per share
- $6.47
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALGS - Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share is tracked under CUSIP 01626L204.
- 34 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 39 to 34 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $26,190,276 to $20,618,673.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 34 institutions filings for Q1 2026.
Security key
01626L204
Latest holder period
Q1 2026
13F holders
34
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
ALGS full holder history
Aligos Therapeutics, Inc. SEC filings
Aligos Therapeutics, Inc. company facts
Aligos Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01626L204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ALGS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 10% | $2,809,000 | 530,000 | Alyeska Investment Group, L.P. | 31 Mar 2025 | |||
| Sio Capital Management, LLC | 5.5% | -0.6% | $3,104,058 | -$184,800 | 335,937 | -5.6% | Sio Capital Management, LLC | 31 Dec 2025 |
| BLATT LAWRENCE | 5.1% | +63% | $2,472,880 | +$956,483 | 286,213 | +63% | Lawrence M. Blatt | 31 Mar 2026 |
| Woodline Partners LP | 4.4% | -20% | $2,068,088 | -$430,332 | 239,362 | -17% | Woodline Partners LP | 31 Mar 2026 |
| EcoR1 Capital, LLC | 3.9% | $1,116,360 | 210,634 | EcoR1 Capital, LLC | 31 Mar 2025 | |||
| Adage Capital Management, L.P. | 3.9% | -61% | $1,514,100 | -$829,150 | 210,000 | -35% | Adage Capital Management, L.P. | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $998,721 | 188,438 | Armistice Capital, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 34 institutional investors reported holding 2,775,086 shares of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS). This represents 49% of the company’s total 5,612,020 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 7.9% | 444,110 | 0% | 0.07% | $3,299,737 |
| Alyeska Investment Group, L.P. | 7.3% | 412,000 | 0% | 0.01% | $3,061,160 |
| Sio Capital Management, LLC | 5.8% | 327,237 | -2.6% | 0.35% | $2,431,371 |
| MARSHALL WACE, LLP | 4.8% | 267,135 | -0.57% | 0% | $1,984,813 |
| BANK OF AMERICA CORP /DE/ | 4.1% | 229,754 | +1653% | 0% | $1,707,072 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 178,262 | 0% | 0% | $1,324,487 |
| Woodline Partners LP | 3.2% | 177,362 | -39% | 0% | $1,317,800 |
| SummitTX Capital, L.P. | 2.7% | 148,799 | +6.7% | 0.04% | $1,105,577 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 100,450 | +18% | 0% | $746,344 |
| BAKER BROS. ADVISORS LP | 1.5% | 83,055 | 0% | 0% | $617,099 |
| HHLR ADVISORS, LTD. | 1.4% | 76,247 | 0% | 0.03% | $566,515 |
| CITADEL ADVISORS LLC | 0.97% | 54,311 | +4.8% | 0% | $403,531 |
| LPL Financial LLC | 0.92% | 51,500 | -22% | 0% | $382,645 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.89% | 49,975 | +4.7% | 0% | $371,473 |
| UBS Group AG | 0.66% | 37,061 | +10082% | 0% | $275,363 |
| VANGUARD FIDUCIARY TRUST CO | 0.51% | 28,437 | 0% | 0% | $211,287 |
| TWO SIGMA INVESTMENTS, LP | 0.41% | 23,093 | -71% | 0% | $171,581 |
| Verition Fund Management LLC | 0.34% | 18,887 | -73% | 0% | $140,330 |
| XTX Topco Ltd | 0.25% | 14,196 | -38% | 0% | $105,476 |
| BlackRock, Inc. | 0.23% | 13,040 | 0% | 0% | $96,887 |
| D. E. Shaw & Co., Inc. | 0.2% | 10,978 | 0% | $81,567 | |
| Quadrature Capital Ltd | 0.19% | 10,822 | 0% | $80,407 | |
| Rockefeller Capital Management L.P. | 0.18% | 10,000 | 0% | 0% | $74,300 |
| Golden State Wealth Management, LLC | 0.05% | 2,674 | 0% | 0% | $19,868 |
| ROYAL BANK OF CANADA | 0.04% | 2,125 | 0% | 0% | $16,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,775,086 | $20,618,673 | -$479,274 | $7.43 | 34 |
| 2025 Q4 | 2,811,051 | $26,190,276 | +$1,301,467 | $9.32 | 39 |
| 2025 Q3 | 2,651,648 | $25,986,937 | +$21,301 | $9.80 | 33 |
| 2025 Q2 | 2,706,213 | $19,511,284 | -$4,851,101 | $7.21 | 37 |
| 2025 Q1 | 3,295,608 | $27,078,858 | +$7,676,587 | $8.25 | 35 |
| 2024 Q4 | 1,619,199 | $64,508,583 | +$11,813,062 | $39.84 | 33 |
| 2024 Q3 | 1,692,019 | $14,651,229 | +$14,572,683 | $8.66 | 27 |